Product review on the monoclonal antibody palivizumab for prevention of respiratory syncytial virus infection

References

• Taylor G. Animal models of respiratory syncytial virus infection. Vaccine 2017; 35(3):469-80; PMID:27908639; https://doi.org/10.1016/j.vaccine.2016.11.054
   PubMed Web of Science ®Google Scholar
• Rodriguez WJ. Respiratory syncytial virus infections. Pediatr Infect Dis J 1999; 10(3):161-8
   Google Scholar
• Tawar RG, Duquerroy S, Vonrhein C, Varela PF, Damier-Piolle L, Castagné N, MacLellan K, Bedouelle H, Bricogne G, Bhella D, et al. Crystal structure of a nucleocapsid-like nucleoprotein-RNA complex of respiratory syncytial virus. Science 2009; 326(5957):1279-83; PMID:19965480; https://doi.org/10.1126/science.1177634
   PubMed Web of Science ®Google Scholar
• Simoes EA. Respiratory syncytial virus infection. Lancet 1999; 354(9181):847-52; PMID:10485741; https://doi.org/10.1016/S0140-6736(99)80040-3
   PubMed Web of Science ®Google Scholar
• Bont L, Kimpen JL. Immunological mechanisms of severe respiratory syncytial virus bronchiolitis. Intensive Care Med 2002; 28(5):616-21; PMID:12029411; https://doi.org/10.1007/s00134-002-1256-z
   PubMed Web of Science ®Google Scholar
• Bont L, Versteegh J, Swelsen WT, Heijnen CJ, Kavelaars A, Brus F, Draaisma JM, Pekelharing-Berghuis M, van Diemen-Steenvoorde RA, Kimpen JL. Natural reinfection with respiratory syncytial virus does not boost virus-specific T-cell immunity. Pediatr Res 2002; 52(3):363-7; PMID:12193668; https://doi.org/10.1203/00006450-200209000-00009
   PubMed Web of Science ®Google Scholar
• Rossi GA, Colin AA. Respiratory syncytial virus - host interaction in the pathogenesis of bronchiolitis and its impact on respiratory morbidity in later life. Pediatr Allergy Immunol 2017 [Epub ahead of print]; https://doi.org/10.1111/pai.12716.
   Web of Science ®Google Scholar
• Rey-Jurado E, Kalergis AM. Immunological features of respiratory syncytial virus-caused pneumonia-implications for vaccine design. Int J Mol Sci 2017; 18(3). pii: E556; PMID:28561768; https://doi.org/10.3390/ijms18030556
   PubMed Web of Science ®Google Scholar
• Bont L, Baraldi E, Fauroux B, Greenough A, Heikkinen T, Manzoni P, Martinón-Torres F, Nair H, Papadopoulos NG, ReSViNET. RSV–still more questions than answers. Pediatr Infect Dis J 2014; 33(11):1177-9; PMID:25162928; https://doi.org/10.1097/INF.0000000000000535
   PubMed Web of Science ®Google Scholar
• Sommer C, Resch B, Simões EA. Risk factors for severe respiratory syncytial virus lower respiratory tract infection. Open Microbiol J 2011; 5:144-54; PMID:22262987; https://doi.org/10.2174/1874285801105010144
   PubMedGoogle Scholar
• Resch B. Burden of respiratory syncytial virus infection in young children. World J Clin Pediatr 2012; 1(3):8-12; PMID:25254161; https://doi.org/10.5409/wjcp.v1.i3.8
   PubMedGoogle Scholar
• Resch B, Sommer C, Nuijten MJ, Seidinger S, Walter E, Schoellbauer V, Mueller WD. Cost-effectiveness of palivizumab for respiratory syncytial virus infection in high-risk children, based on long-term epidemiologic data from Austria. Pediatr Infect Dis J 2012; 31(1):e1-8; PMID:21960187; https://doi.org/10.1097/INF.0b013e318235455b
   PubMed Web of Science ®Google Scholar
• Hall CB, Simőes EA, Anderson LJ. Clinical and epidemiologic features of respiratory syncytial virus. Curr Top Microbiol Immunol 2013; 372:39-57; PMID:24362683; https://doi.org/10.1007/978-3-642-38919-1_2
   PubMed Web of Science ®Google Scholar
• Meissner HC. Viral bronchiolitis in children. N Engl J Med 2016; 374:62-72; PMID:26735994; https://doi.org/10.1056/NEJMra1413456
   PubMed Web of Science ®Google Scholar
• Bont L, Checchia PA, Fauroux B, Figueras-Aloy J, Manzoni P, Paes B, Simões EA, Carbonell-Estrany X. Defining the epidemiology and burden of severe respiratory syncytial virus infection among infants and children in western countries. Infect Dis Ther 2016; 5(3):271-98; PMID:27480325; https://doi.org/10.1007/s40121-016-0123-0
   PubMed Web of Science ®Google Scholar
• Haynes AK, Prill MM, Iwane MK, Gerber SI. Respiratory syncytial virus—United States, July 2012–June 2014. MMWR Morb Mortal Wkly Rep 2014; 63:1133-36; PMID:25474034
   PubMed Web of Science ®Google Scholar
• Nair H, Nokes DJ, Gessner BD, Dherani M, Madhi SA, Singleton RJ, O'Brien KL, Roca A, Wright PF, Bruce N, et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: A systematic review and meta-analysis. Lancet 2010; 375:1545-55; PMID:20399493; https://doi.org/10.1016/S0140-6736(10)60206-1
   PubMed Web of Science ®Google Scholar
• Hall CB, Weinberg GA, Iwane MK, Blumkin AK, Edwards KM, Staat MA, Auinger P, Griffin MR, Poehling KA, Erdman D, et al. The burden of respiratory syncytial virus infection in young children. N Engl J Med 2009; 360(6):588-98; PMID:19196675; https://doi.org/10.1056/NEJMoa0804877
   PubMed Web of Science ®Google Scholar
• Ralston S, Hill V. Incidence of apnea in infants hospitalized with respiratory syncytial virus bronchiolitis: A systematic review. J Pediatr 2009; 155(5):728-33; PMID:19647839; https://doi.org/10.1016/j.jpeds.2009.04.063
   PubMed Web of Science ®Google Scholar
• Morichi S, Morishita N, Ishida Y, Oana S, Yamanaka G, Kashiwagi Y, Kawashima H. Examination of neurological prognostic markers in patients with respiratory syncytial virus-associated encephalopathy. Int J Neurosci 2017; 127(1):44-50; PMID:26732732; https://doi.org/10.3109/00207454.2016.1138951
   PubMed Web of Science ®Google Scholar
• Sigurs N, Aljassim F, Kjellman B, Robinson PD, Sigurbergsson F, Bjarnason R, Gustafsson PM. Asthma and allergy patterns over 18 years after severe RSV bronchiolitis in the first year of life. Thorax 2010; 65(12):1045-52; PMID:20581410; https://doi.org/10.1136/thx.2009.121582
   PubMed Web of Science ®Google Scholar
• Mejias A, Ramilo O. New options in the treatment of respiratory syncytial virus disease. J Infect 2015; 71(Suppl 1):S80-7; PMID:25922289; https://doi.org/10.1016/j.jinf.2015.04.025
   PubMed Web of Science ®Google Scholar
• Flamant C, Hallalel F, Nolent P, Chevalier JY, Renolleau S. Severe respiratory syncytial virus bronchiolitis in children: From short mechanical ventilation to extracorporeal membrane oxygenation. Eur J Pediatr 2005; 164(2):93-8; PMID:15703980; https://doi.org/10.1007/s00431-004-1580-0
   PubMed Web of Science ®Google Scholar
• Liu F, Ouyang J, Sharma AN, Liu S, Yang B, Xiong W, Xu R. Leukotriene inhibitors for bronchiolitis in infants and young children. Cochrane Database Syst Rev 2015; (3):CD010636; PMID:25773054; https://doi.org/10.1002/14651858.CD010636.pub2.
   PubMed Web of Science ®Google Scholar
• Ventre K, Randolph A. Ribavirin for respiratory syncytial virus infection of the lower respiratory tract in infants and young children. Cochrane Database Syst Rev 2010; (5):CD000181; PMID:20464715; https://doi.org/10.1002/14651858.CD000181.pub4
   PubMedGoogle Scholar
• Taylor G. Animal models of respiratory syncytial virus infection. Vaccine 2017; 35(3):469-80; PMID:27908639; https://doi.org/10.1016/j.vaccine.2016.11.054
   PubMed Web of Science ®Google Scholar
• Hemming VG, Prince GA. Intravenous immunoglobulin G in viral respiratory infections for newborns and infants. Pediatr Infect Dis 1986; 5(3 Suppl):S204-6; PMID:3714525
   PubMedGoogle Scholar
• Prince GA, Hemming VG, Chanock RM. The use of purified immunoglobulin in the therapy of respiratory syncytial virus infection. Pediatr Infect Dis 1986; 5(3 Suppl):S201-3; PMID:3714524
   PubMedGoogle Scholar
• Groothuis JR, Levin MJ, Rodriguez W, Hall CB, Long CE, Kim HW, Lauer BA, Hemming VG. Use of intravenous gamma globulin to passively immunize high-risk children against respiratory syncytial virus: Safety and pharmacokinetics. The RSVIG Study Group. Antimicrob Agents Chemother 1991; 35(7):1469-73; PMID:1718213; https://doi.org/10.1128/AAC.35.7.1469
   PubMed Web of Science ®Google Scholar
• Groothuis JR, Simoes EAF, Levin MJ, Hall CB, Long CE, Rodriguez WJ, Arrobio J, Meissner HC, Fulton DR, Welliver RC, et al. Hemming VG: Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. N Engl J Med 1993; 329:1524-30; PMID:8413475; https://doi.org/10.1056/NEJM199311183292102
   PubMed Web of Science ®Google Scholar
• Simoes EA, Sondheimer HM, Top FH Jr, Meissner HC, Welliver RC, Kramer AA, Groothuis JR. Respiratory syncytial virus immune globulin for prophylaxis against respiratory syncytial virus disease in infants and children with congenital heart disease. The Cardiac Study Group. J Pediatr 1998; 133:492-9; PMID:9787686; https://doi.org/10.1016/S0022-3476(98)70056-3
   PubMed Web of Science ®Google Scholar
• American Academy of Paediatrics. Respiratory syncytial virus immune globulin intravenous: Indications for use. Pediatrics 1997; 99:645-50; PMID:9093323; https://doi.org/10.1542/peds.99.4.645
   PubMed Web of Science ®Google Scholar
• Resch B. Palivizumab for the prophylaxis of respiratory syncytial virus infection. Pediatric Health 2008; 2(3):265-78; https://doi.org/10.2217/17455111.2.3.265
   Google Scholar
• Beeler JA, van Wyke Coelingh K. Neutralizing epitoptes of the F glycoprotein of respiratory syncytial virus: Effect of mutation upon fusion function. J Virol 1989; 63:2941-50; PMID:2470922
   PubMed Web of Science ®Google Scholar
• Young J. Development of a potent respiratory syncytial virus-specific monoclonal antibody for the prevention of serious lower respiratory tract disease in infants. Respir Med 2002; 96(Suppl B):S31-35; PMID:11996402; https://doi.org/10.1053/rmed.2002.1298
   PubMed Web of Science ®Google Scholar
• Johnson S, Oliver C, Prince GA, Hemming VG, Pfarr DS, Wang SC, Dormitzer M, O'Grady J, Koenig S, Tamura JK, et al. Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. J Infect Dis 1997; 176:1215-24; PMID:9359721; https://doi.org/10.1086/514115
   PubMed Web of Science ®Google Scholar
• DeVincenzo JP, Hall CB, Kimberlin DW, Sánchez PJ, Rodriguez WJ, Jantausch BA, Corey L, Kahn JS, Englund JA, Suzich JA, et al. Surveillance of clinical isolates of respiratory syncytial virus for palivizumab (Synagis)-resistant mutants. J Infect Dis 2004; 190(5):975-8; PMID:15295704; https://doi.org/10.1086/423213
   PubMed Web of Science ®Google Scholar
• Johnson S, Griego SD, Pfarr DS, Doyle ML, Woods R, Carlin D, Prince GA, Koenig S, Young JF, Dillon SB. A direct comparison of the activities of two humanized respiratory syncytial virus monoclonal antibodies: MEDI-493 and RSHZ19. J Infect Dis 1999; 180:35-40; PMID:10353858; https://doi.org/10.1086/314846
   PubMed Web of Science ®Google Scholar
• Papenburg J, Carbonneau J, Hamelin ME, Isabel S, Bouhy X, Ohoumanne N, Déry P, Paes BA, Corbeil J, Bergeron MG, et al. Molecular evolution of respiratory syncytial virus fusion gene, Canada, 2006-2010. Emerg Infect Dis 2012; 18(1):120-4; PMID:22264682; https://doi.org/10.3201/eid1801.110515
   PubMed Web of Science ®Google Scholar
• Piedimonte G, King KA, Holmgren NL, Bertrand PJ, Rodriguez MM, Hirsch RL. A humanized monoclonal antibody against respiratory syncytial virus (palivizumab) inhibits RSV-induced neurogenic-mediated inflammation in rat airways. Pediatr Res 2000; 47(3):351-6; PMID:10709734; https://doi.org/10.1203/00006450-200003000-00011
   PubMed Web of Science ®Google Scholar
• DeVincenzo JP, Aitken J, Harrison L. Respiratory syncytial virus (RSV) loads in premature infants with and without prophylactic RSV fusion protein monoclonal antibody. J Pediatr 2003; 143:123-6; PMID:12915838; https://doi.org/10.1016/S0022-3476(03)00213-0
   PubMed Web of Science ®Google Scholar
• Malley R, DeVincenzo J, Ramilo O, Dennehy PH, Meissner HC, Gruber WC, Sanchez PJ, Jafri H, Balsley J, Carlin D, et al. Reduction of respiratory syncytial virus (RSV) in tracheal aspirates in intubated infants by use of humanized monoclonal antibody to RSV F protein. J Infect Dis 1998; 178:1555-61; PMID:9815203; https://doi.org/10.1086/314523
   PubMed Web of Science ®Google Scholar
• Sáez-Llorens X, Castaño E, Null D, Steichen J, Sánchez PJ, Ramilo O, Top FH Jr, Connor E. Safety and pharmacokinetics of an intramuscular humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. The MEDI-493 study group. Pediatr Infect Dis J 1998; 17(9):787-91; PMID:9779762; https://doi.org/10.1097/00006454-199809000-00007
   PubMed Web of Science ®Google Scholar
• MedImmune Inc. Synagis® (palivizumab) [online]. Available from URL: https://www.synagis.com/ [accessed 2017 Feb 7]
   Google Scholar
• Feltes TF, Cabalka AK, Meissner C, Piazza FM, Carlin DA, Top FH Jr, Connor EM, Sondheimer HM. Palivizumab prophylaxis reduces hospitalisation due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr 2003; 143:532-40; PMID:14571236; https://doi.org/10.1067/S0022-3476(03)00454-2
   PubMed Web of Science ®Google Scholar
• Fenton C, Scott LJ, Plosker GL. Palivizumab as prophylaxis for respiratory syncytial virus. Pediatric Drugs 2004; 6:177-97; PMID:15170364; https://doi.org/10.2165/00148581-200406030-00004
   PubMedGoogle Scholar
• Subramanian KN, Weisman LE, Rhodes T, Ariagno R, Sánchez PJ, Steichen J, Givner LB, Jennings TL, Top FH Jr, Carlin D, et al. Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. MEDI-493 study group. Pediatr Infect Dis J 1998; 17(2):110-5; PMID:9493805; https://doi.org/10.1097/00006454-199802000-00006
   PubMed Web of Science ®Google Scholar
• [No authors listed]. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group. Pediatrics 1998; 102(3 Pt 1):531-7.
   Web of Science ®Google Scholar
• Feltes TF, Cabalka AK, Meissner HC, Piazza FM, Carlin DA, Top FH Jr, Connor EM, Sondheimer HM, Cardiac Synagis Study Group. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr 2003; 143(4):532-40; PMID:14571236; https://doi.org/10.1067/S0022-3476(03)00454-2
   PubMed Web of Science ®Google Scholar
• Groothuis JR. Safety and tolerance of palivizumab administration in a large Northern Hemisphere trial. Northern Hemisphere expanded access study group. Pediatr Infect Dis J 2001; 20(6):628-30; PMID:11419509; https://doi.org/10.1097/00006454-200106000-00018
   PubMed Web of Science ®Google Scholar
• Groothuis JR. Safety of palivizumab in preterm infants 29 to 32 weeks' gestational age without chronic lung disease to prevent serious respiratory syncytial virus infection. Eur J Clin Microbiol Infect Dis 2003; 22(7):414-7; PMID:12827537; https://doi.org/10.1007/s10096-003-0961-z
   PubMed Web of Science ®Google Scholar
• Lacaze-Masmonteil T, Seidenberg J, Mitchell I, Cossey V, Cihar M, Csader M, Baarsma R, Valido M, Pollack PF, Groothuis JR, et al. Evaluation of the safety of palivizumab in the second season of exposure in young children at risk for severe respiratory syncytial virus infection. Drug Saf 2003; 26(4):283-91; PMID:12608889; https://doi.org/10.2165/00002018-200326040-00005
   PubMed Web of Science ®Google Scholar
• Andabaka T, Nickerson JW, Rojas-Reyes MX, Rueda JD, Bacic Vrca V, Barsic B. Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children. Cochrane Database Syst Rev 2013; (4):CD006602; PMID:23633336; https://doi.org/10.1002/14651858.CD006602.pub4
   PubMed Web of Science ®Google Scholar
• Wang D, Bayliss S, Meads C. Palivizumab for immunoprophylaxis of respiratory syncytial virus (RSV) bronchiolitis in high-risk infants and young children: A systematic review and additional economic modelling of subgroup analyses. Health Technol Assess 2011; 15(5):iii-iv, 1-124; PMID:21281564; https://doi.org/10.3310/hta15050
   PubMed Web of Science ®Google Scholar
• Checchia PA, Nalysnyk L, Fernandes AW, Mahadevia PJ, Xu Y, Fahrbach K, Welliver RC Sr. Mortality and morbidity among infants at high risk for severe respiratory syncytial virus infection receiving prophylaxis with palivizumab: A systematic literature review and meta-analysis. Pediatr Crit Care Med 2011; 12(5):580-8; PMID:21200358; https://doi.org/10.1097/PCC.0b013e3182070990
   PubMed Web of Science ®Google Scholar
• Simoes EA, Groothuis JR. Respiratory syncytial virus prophylaxis–the story so far. Respir Med 2002; 96(Suppl B):S15-24; PMID:11996400; https://doi.org/10.1053/rmed.2002.1296
   PubMed Web of Science ®Google Scholar
• [No authors listed]. Prevention of respiratory syncytial virus infections: Indications for the use of palivizumab and update on the use of RSV-IGIV. American academy of pediatrics committee on infectious diseases and committee of fetus and newborn. Pediatrics 1998; 102(5):1211-6; PMID:9794957; https://doi.org/10.1542/peds.102.5.1211
   PubMed Web of Science ®Google Scholar
• American Academy of Pediatrics Committee on Infectious Diseases and Committee on Fetus and Newborn. Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections. Pediatrics 2003; 112(6 Pt 1):1442-6; PMID:14654627
   PubMedGoogle Scholar
• Committee on Infectious Diseases. From the American Academy of Pediatrics: Policy statements–Modified recommendations for use of palivizumab for prevention of respiratory syncytial virus infections. Pediatrics 2009; 124(6):1694-701; PMID:19736258; https://doi.org/10.1542/peds.2009-2345
   PubMed Web of Science ®Google Scholar
• Resch B. Palivizumab in preventing respiratory syncytial virus-related hospitalization in high-risk infants. Expert Rev Pharmacoecon Outcomes Res 2008; 8(6):529-38; PMID:20528363; https://doi.org/10.1586/14737167.8.6.529
   PubMedGoogle Scholar
• American Academy of Pediatrics Committee on Infectious Diseases, American Academy of Pediatrics Bronchiolitis Guidelines Committee. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. Pediatrics 2014; 134(2):415-20; PMID:25070315; https://doi.org/10.1542/peds.2014-1665
   PubMed Web of Science ®Google Scholar
• Resch B. Respiratory syncytial virus infection in high-risk infants - an update on palivizumab prophylaxis. Open Microbiol J 2014; 8:71-7; PMID:25132870; https://doi.org/10.2174/1874285801408010071
   PubMedGoogle Scholar
• Manzoni P, Paes B, Resch B, Carbonell-Estrany X, Bont L. High risk for RSV bronchiolitis in late preterms and selected infants affected by rare disorders: A dilemma of specific prevention. Early Hum Dev 2012; 88(Suppl 2):S34-41; PMID:22633511; https://doi.org/10.1016/S0378-3782(12)70012-9
   PubMedGoogle Scholar
• Paes B, Mitchell I, Li A, Lanctôt KL. Respiratory hospitalizations and respiratory syncytial virus prophylaxis in special populations. Eur J Pediatr 2012; 171(5):833-41; PMID:22203430; https://doi.org/10.1007/s00431-011-1654-8
   PubMed Web of Science ®Google Scholar
• Resch B, Paes B. Are late preterm infants as susceptible to RSV infection as full term infants? Early Hum Dev 2011; 87(Suppl 1):S47-9; PMID:21276672; https://doi.org/10.1016/j.earlhumdev.2011.01.010
   PubMed Web of Science ®Google Scholar
• Resch B, Manzoni P, Lanari M. Severe respiratory syncytial virus (RSV) infection in infants with neuromuscular diseases and immune deficiency syndromes. Paediatr Respir Rev 2009; 10(3):148-53; PMID:19651386; https://doi.org/10.1016/j.prrv.2009.06.003
   PubMed Web of Science ®Google Scholar
• van Beek D, Paes B, Bont L. Increased risk of RSV infection in children with Down's syndrome: Clinical implementation of prophylaxis in the European Union. Clin Dev Immunol 2013; 2013:801581; PMID:23878586; https://doi.org/10.1155/2013/801581
   PubMedGoogle Scholar
• Yi H, Lanctôt KL, Bont L, Bloemers BL, Weijerman M, Broers C, Li A, Kiss A, Mitchell I, Paes B, et al. Respiratory syncytial virus prophylaxis in Down syndrome: A prospective cohort study. Pediatrics 2014; 133(6):1031-7; PMID:24799541; https://doi.org/10.1542/peds.2013-3916
   PubMed Web of Science ®Google Scholar
• Blanken MO, Rovers MM, Molenaar JM, Winkler-Seinstra PL, Meijer A, Kimpen JL, Bont L, Dutch RSV Neonatal Network. Respiratory syncytial virus and recurrent wheeze in healthy preterm infants. N Engl J Med 2013; 368(19):1791-9; PMID:23656644; https://doi.org/10.1056/NEJMoa1211917
   PubMed Web of Science ®Google Scholar
• American Academy of Pediatrics Committee on Infectious Diseases, American Academy of Pediatrics Bronchiolitis Guidelines Committee. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. Pediatrics 2014; 134(2):e620-38; PMID:25070304; https://doi.org/10.1542/peds.2014-1666
   PubMed Web of Science ®Google Scholar
• Anderson EJ, Krilov LR, DeVincenzo JP, Checchia PA, Halasa N, Simões EA, Domachowske JB, Forbes ML, Pannaraj PS, McBride SJ, et al. SENTINEL1: An observational study of respiratory syncytial virus hospitalizations among U.S. Infants Born at 29 to 35 weeks' gestational age not receiving immunoprophylaxis. Am J Perinatol 2017; 34(1):51-61; PMID:27233106; https://doi.org/10.1055/s-0036-1584147
   PubMed Web of Science ®Google Scholar
• Zuccotti G, Fabiano V. Indications to respiratory syncytial virus immunoprophylaxis in the 29-32 wGA group: Is there still room for debating? Ital J Pediatr 2017; 43(1):17; PMID:28257653; https://doi.org/10.1186/s13052-017-0341-4
   PubMed Web of Science ®Google Scholar
• Cetinkaya M, Oral TK, Karatekin S, Cebeci B, Babayigit A, Yesil Y. Efficacy of palivizumab prophylaxis on the frequency of RSV-associated lower respiratory tract infections in preterm infants: Determination of the ideal target population for prophylaxis. Eur J Clin Microbiol Infect Dis 2017; PMID:28391538; https://doi.org/10.1007/s10096-017-2976-x
   PubMed Web of Science ®Google Scholar
• Rajah B, Sánchez PJ, Garcia-Maurino C, Leber A, Ramilo O, Mejias A. Impact of the updated guidance for palivizumab prophylaxis against respiratory syncytial virus infection: A single center experience. J Pediatr 2017; 181:183-8. e1 reporting increased morbidity 29-34; PMID:27855996; https://doi.org/10.1016/j.jpeds.2016.10.074
   PubMed Web of Science ®Google Scholar
• Yogev R, Krilov LR, Fergie JE, Weiner LB. Re-evaluating the new committee on infectious diseases recommendations for palivizumab use in premature infants. Pediatr Infect Dis J 2015; 34(9):958-60; PMID:26107347; https://doi.org/10.1097/INF.0000000000000808
   PubMed Web of Science ®Google Scholar
• Grindeland CJ, Mauriello CT, Leedahl DD, Richter LM, Meyer AC. Association between updated guideline-based palivizumab administration and hospitalizations for respiratory syncytial virus infections. Pediatr Infect Dis J 2016; 35(7):728-32; PMID:27078122; https://doi.org/10.1097/INF.0000000000001150
   PubMed Web of Science ®Google Scholar
• Ambrose CS. Statistical power to detect an association between guideline-based palivizumab administration and hospitalizations for respiratory syncytial virus infections. Pediatr Infect Dis J 2017; 36(3):348; PMID:28187116; https://doi.org/10.1097/INF.0000000000001432
   PubMed Web of Science ®Google Scholar
• Grindeland CJ, Leedahl DD. In reply: Statistical power to detect an association between guideline-based palivizumab administration and hospitalizations for respiratory syncytial virus infections. Pediatr Infect Dis J 2017; 36(3):348-9; PMID:28187117; https://doi.org/10.1097/INF.0000000000001433
   PubMed Web of Science ®Google Scholar
• Newby B, Sorokan T. Respiratory syncytial virus infection rates with limited use of palivizumab for infants born at 29 to 31+6/7 weeks gestational age. Can J Hosp Pharm 2017; 70(1):13-8; PMID:28348428
   PubMedGoogle Scholar
• Pignotti MS, Carmela Leo M, Pugi A, De Masi S, Biermann KP, Galli L, Vitali Rosati G, Buonocore G, Mugelli A, Dani C, et al. Consensus conference on the appropriateness of palivizumab prophylaxis in respiratory syncytial virus disease. Pediatr Pulmonol 2016; 51(10):1088-96; PMID:27618642; https://doi.org/10.1002/ppul.23561
   PubMed Web of Science ®Google Scholar
• Robbie GJ, Zhao L, Mondick J, Losonsky G, Roskos LK. Population pharmacokinetics of palivizumab, a humanized anti-respiratory syncytial virus monoclonal antibody, in adults and children. Antimicrob Agents Chemother 2012; 56(9):4927-36; PMID:22802243; https://doi.org/10.1128/AAC.06446-11
   PubMed Web of Science ®Google Scholar
• Gutfraind A, Galvani AP, Meyers LA. Efficacy and optimization of palivizumab injection regimens against respiratory syncytial virus infection. JAMA Pediatr 2015; 169(4):341-8; PMID:25706618; https://doi.org/10.1001/jamapediatrics.2014.3804
   PubMed Web of Science ®Google Scholar
• Lavoie PM, Solimano A, Taylor R, Kwan E, Claydon J, Turvey SE, Marr N. Outcomes of respiratory syncytial virus immunoprophylaxis in infants using an abbreviated dosing regimen of palivizumab. JAMA Pediatr 2016; 170(2):174-6; PMID:26720836; https://doi.org/10.1001/jamapediatrics.2015.3235
   PubMed Web of Science ®Google Scholar
• Manzoni P, Paes B, Lanctôt KL, Dall'Agnola A, Mitchell I, Calabrese S, Maule M, Girardi E, Harimoto T, Li A. Outcomes of infants receiving palivizumab prophylaxis for respiratory syncytial virus in canada and italy: An international, prospective cohort study. Pediatr Infect Dis J 2017; 36(1):2-8; PMID:27649365; https://doi.org/10.1097/INF.0000000000001340
   PubMed Web of Science ®Google Scholar
• Resch B, Egger B, Kurath-Koller S, Urlesberger B. Respiratory syncytial virus hospitalizations in infants of 28 weeks gestational age and less in the palivizumab era. Int J Infect Dis 2017; 57:50-3; PMID:28163166; https://doi.org/10.1016/j.ijid.2017.01.034
   PubMed Web of Science ®Google Scholar
• Resch B, Bramreiter VS, Kurath-Koller S, Freidl T, Urlesberger B. Respiratory syncytial virus associated hospitalizations in preterm infants of 29 to 32 weeks gestational age using a risk score tool for palivizumab prophylaxis. Eur J Clin Microbiol Infect Dis 2017; 36(6):1057-1062; PMID:28078558; https://doi.org/10.1007/s10096-016-2891-6
   PubMed Web of Science ®Google Scholar
• Wang DY, Li A, Paes B, Mitchell I, Lanctôt KL, CARESS Investigators. First versus second year respiratory syncytial virus prophylaxis in chronic lung disease (2005-2015). Eur J Pediatr 2017; 176(3):413-22. 2.3 – 3.9% RSVH rate; PMID:28105526; https://doi.org/10.1007/s00431-017-2849-4
   PubMed Web of Science ®Google Scholar
• Resch B, Kurath-Koller S, Hahn J, Raith W, Köstenberger M, Gamillscheg A. Respiratory syncytial virus-associated hospitalizations over three consecutive seasons in children with congenital heart disease. Eur J Clin Microbiol Infect Dis 2016; 35(7):1165-9; PMID:27126331; https://doi.org/10.1007/s10096-016-2649-1
   PubMed Web of Science ®Google Scholar
• Kim AY, Jung SY, Choi JY, Kim GB, Kim YH, Shim WS, Kang IS, Jung JW. Retrospective multicenter study of respiratory syncytial virus prophylaxis in korean children with congenital heart diseases. Korean Circ J 2016; 46(5):719-26; PMID:27721865; https://doi.org/10.4070/kcj.2016.46.5.719
   PubMed Web of Science ®Google Scholar
• Sánchez-Luna M, Medrano C, Lirio J, RISK-21 Study Group. Down syndrome as risk factor for respiratory syncytial virus hospitalization: A prospective multicenter epidemiological study. Influenza Other Respir Viruses 2017; 11(2):157-64. 9.7% RSV hosp rate; PMID:27611835; https://doi.org/10.1111/irv.12431
   PubMed Web of Science ®Google Scholar
• Metz J, Eber E, Resch B. Respiratory syncytial virus infection associated hospitalization rates in infants and children with cystic fibrosis. Pediatr Infect Dis J 2017; 36(6):545-548.
   PubMed Web of Science ®Google Scholar
• Thorburn K. Pre-existing disease is associated with a significantly higher risk of death in severe respiratory syncytial virus infection. Arch Dis Child 2009; 94(2):99-103; PMID:18653625; https://doi.org/10.1136/adc.2008.139188
   PubMed Web of Science ®Google Scholar
• French CE, McKenzie BC, Coope C, Rajanaidu S, Paranthaman K, Pebody R, Nguyen-Van-Tam JS, Noso-RSV Study Group, Higgins JP, Beck CR. Risk of nosocomial respiratory syncytial virus infection and effectiveness of control measures to prevent transmission events: A systematic review. Influenza Other Respir Viruses 2016; 10(4):268-90; PMID:26901358; https://doi.org/10.1111/irv.12379
   PubMed Web of Science ®Google Scholar
• Wu H, Pfarr DS, Johnson S, Brewah YA, Woods RM, Patel NK, White WI, Young JF, Kiener PA. Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract. J Mol Biol 2007; 368(3):652-65; PMID:17362988; https://doi.org/10.1016/j.jmb.2007.02.024
   PubMed Web of Science ®Google Scholar
• Lagos R, DeVincenzo JP, Muñoz A, Hultquist M, Suzich J, Connor EM, Losonsky GA. Safety and antiviral activity of motavizumab, a respiratory syncytial virus (RSV)-specific humanized monoclonal antibody, when administered to RSV-infected children. Pediatr Infect Dis J 2009; 28(9):835-7; PMID:19636278; https://doi.org/10.1097/INF.0b013e3181a165e4
   PubMed Web of Science ®Google Scholar
• Carbonell-Estrany X, Simões EA, Dagan R, Hall CB, Harris B, Hultquist M, Connor EM, Losonsky GA, Motavizumab Study Group. Motavizumab for prophylaxis of respiratory syncytial virus in high-risk children: A noninferiority trial. Pediatrics 2010; 125(1):e35-51; PMID:20008423; https://doi.org/10.1542/peds.2008-1036
   PubMed Web of Science ®Google Scholar
• Fernández P, Trenholme A, Abarca K, Griffin MP, Hultquist M, Harris B, Losonsky GA, Motavizumab Study Group. A phase 2, randomized, double-blind safety and pharmacokinetic assessment of respiratory syncytial virus (RSV) prophylaxis with motavizumab and palivizumab administered in the same season. BMC Pediatr 2010; 10:38; PMID:20525274; https://doi.org/10.1186/1471-2431-10-38
   PubMed Web of Science ®Google Scholar
• Feltes TF, Sondheimer HM, Tulloh RM, Harris BS, Jensen KM, Losonsky GA, Griffin MP, Motavizumab Cardiac Study Group. A randomized controlled trial of motavizumab versus palivizumab for the prophylaxis of serious respiratory syncytial virus disease in children with hemodynamically significant congenital heart disease. Pediatr Res 2011; 70(2):186-91; PMID:21522037; https://doi.org/10.1203/PDR.0b013e318220a553
   PubMed Web of Science ®Google Scholar
• O'Brien KL, Chandran A, Weatherholtz R, Jafri HS, Griffin MP, Bellamy T, Millar EV, Jensen KM, Harris BS, Reid R, et al. Efficacy of motavizumab for the prevention of respiratory syncytial virus disease in healthy Native American infants: A phase 3 randomised double-blind placebo-controlled trial. Lancet Infect Dis 2015; 15(12):1398-408; PMID:26511956; https://doi.org/10.1016/S1473-3099(15)00247-9
   PubMed Web of Science ®Google Scholar
• Medscape Medical News. FDA panel nixes licensing request for motavizumab. 2010. Available at http://www.medscape.com/viewarticle/722903 [accessed March 30, 2017]
   Google Scholar
• Wu H, Pfarr DS, Losonsky GA, Kiener PA. Immunoprophylaxis of RSV infection: Advancing from RSV-IGIV to palivizumab and motavizumab. Curr Top Microbiol Immunol 2008; 317:103-23; PMID:17990791
   PubMed Web of Science ®Google Scholar
• Robbie GJ, Criste R, Dall'acqua WF, Jensen K, Patel NK, Losonsky GA, Griffin MP. A novel investigational Fc-modified humanized monoclonal antibody, motavizumab-YTE, has an extended half-life in healthy adults. Antimicrob Agents Chemother 2013; 57(12):6147-53; PMID:24080653; https://doi.org/10.1128/AAC.01285-13
   PubMed Web of Science ®Google Scholar
• Mejias A, Garcia-Maurino C, Rodriguez-Fernandez R, Peeples ME, Ramilo O. Development and clinical applications of novel antibodies for prevention and treatment of respiratory syncytial virus infection. Vaccine 2017; 35:496-502; PMID:27692523; https://doi.org/10.1016/j.vaccine.2016.09.026
   PubMed Web of Science ®Google Scholar
• Parnes C, Guillermin J, Habersang R, Nicholes P, Chawla V, Kelly T, Fishbein J, McRae P, Goessler M, Gatti A, et al. Palivizumab outcomes registry study group. Palivizumab prophylaxis of respiratory syncytial virus disease in 2000-2001: Results from the palivizumab outcomes registry. Pediatr Pulmonol 2003; 35(6):484-9; PMID:12746948; https://doi.org/10.1002/ppul.10288
   PubMed Web of Science ®Google Scholar
• Fenton C, Scott LJ, Plosker GL. Palivizumab: A review of its use as prophylaxis for serious respiratory syncytial virus infection. Paediatr Drugs 2004; 6(3):177-97; PMID:15170364; https://doi.org/10.2165/00148581-200406030-00004
   PubMedGoogle Scholar
• Golombek SG, Berning F, Lagamma EF. Compliance with prophylaxis for respiratory syncytial virus infection in a home setting. Pediatr Infect Dis J 2004; 23(4):318-22; PMID:15071285; https://doi.org/10.1097/00006454-200404000-00008
   PubMed Web of Science ®Google Scholar
• Frogel MP, Stewart DL, Hoopes M, Fernandes AW, Mahadevia PJ. A systematic review of compliance with palivizumab administration for RSV immunoprophylaxis. J Manag Care Pharm 2010; 16(1):46-58; PMID:20131495; https://doi.org/10.18553/jmcp.2010.16.1.46
   PubMed Web of Science ®Google Scholar
• Chan P, Li A, Paes B, Abraha H, Mitchell I, Lanctôt KL, CARESS investigators. Adherence to palivizumab for respiratory syncytial virus prevention in the canadian registry of palivizumab. Pediatr Infect Dis J 2015; 34(12):e290-7; PMID:26780032; https://doi.org/10.1097/INF.0000000000000922
   PubMed Web of Science ®Google Scholar
• Robbie GJ, Makari D, Harris B, Losonsky GA, Jafri HS. Randomized, double-blind study of the pharmacokinetics and safety of palivizumab liquid formulation compared with lyophilized formulation. Infect Dis Ther 2014; 3(2):203-14; PMID:25269648; https://doi.org/10.1007/s40121-014-0042-x
   PubMedGoogle Scholar
• Makari D, Jensen KM, Harris B, Jafri HS. Randomized, double-blind study of the safety of the liquid versus lyophilized formulation of palivizumab in premature infants and children with chronic lung disease of prematurity. Infect Dis Ther 2014; 3(2):339-47; PMID:25156956; https://doi.org/10.1007/s40121-014-0033-y
   PubMedGoogle Scholar
• FDA Synagis (Palivizumab) [online] Available from URL: http://www.accessdata.fda.gov/drugsatfda_docs/label/2002/palimed102302LB.pdf
   Google Scholar
• Mohan AK, Braum M, Ellenberg S, Hedje J, Cote TR. Deaths among children less than two years of age receiving palivizumab: An analysis of comorbiditeis. Pediatr Infect Dis J 2004; 23:342-45; PMID:15071290; https://doi.org/10.1097/00006454-200404000-00013
   PubMed Web of Science ®Google Scholar
• Sáez-Llorens X, Moreno MT, Ramilo O, Sánchez PJ, Top FH Jr, Connor EM, MEDI-493 Study Group. Safety and pharmacokinetics of palivizumab therapy in children hospitalized with respiratory syncytial virus infection. Pediatr Infect Dis J 2004; 23(8):707-12; PMID:15295219; https://doi.org/10.1097/01.inf.0000133165.85909.08
   PubMed Web of Science ®Google Scholar
• Murray J, Saxena S, Sharland M. Preventing severe respiratory syncytial virus disease: passive, active immunisation and new antivirals. Arch Dis Child 2014; 99(5):469-73; PMID:24464977; https://doi.org/10.1136/archdischild-2013-303764
   PubMed Web of Science ®Google Scholar
• RSV Vaccine and mAb Snapshot. 2016. Available from http://www.path.org/vaccineresources/files/RSV-snapshot-December2016.pdf (accessed 7 Feb 2017)
   Google Scholar